Purpose: The purpose of this study was to determine if intravitreal bevacizumab can reduce subretinal exudates and exudative retinal detachment and facilitate the treatment of Coats disease in children.
Methods: Prospective, interventional, and noncomparative case series of three eyes in three children with Coats disease were studied. All eyes received only intravitreal bevacizumab injection as the primary treatment.